Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Recurrence risk of early-stage melanoma of the external ear: an investigation of surgical approach and sentinel lymph node status.

Truong A, Hyngstrom JR, Andtbacka RHI, Noyes RD, Wright M, Snyder J, Winters A, Sause WT, Grossmann KF, Khong HT, Bowen GM, Hitchcock YJ, Grossman D, Bowles TL.

Melanoma Res. 2018 Dec 20. doi: 10.1097/CMR.0000000000000534. [Epub ahead of print]

PMID:
31219456
2.

Mechanistic evidence for tracking the seasonality of photosynthesis with solar-induced fluorescence.

Magney TS, Bowling DR, Logan BA, Grossmann K, Stutz J, Blanken PD, Burns SP, Cheng R, Garcia MA, Kӧhler P, Lopez S, Parazoo NC, Raczka B, Schimel D, Frankenberg C.

Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11640-11645. doi: 10.1073/pnas.1900278116. Epub 2019 May 28.

PMID:
31138693
3.

Essentials when studying child-father attachment: A fundamental view on safe haven and secure base phenomena.

Grossmann K, Grossmann KE.

Attach Hum Dev. 2019 Mar 21:1-6. doi: 10.1080/14616734.2019.1589056. [Epub ahead of print]

PMID:
30898025
4.

Impact of Haloarchaea on Speciation of Uranium-A Multispectroscopic Approach.

Bader M, Rossberg A, Steudtner R, Drobot B, Großmann K, Schmidt M, Musat N, Stumpf T, Ikeda-Ohno A, Cherkouk A.

Environ Sci Technol. 2018 Nov 6;52(21):12895-12904. doi: 10.1021/acs.est.8b02667. Epub 2018 Oct 18.

PMID:
30125086
5.

Universal and culturally specific aspects of sensitive responsiveness to young children.

Grossmann KE, Grossmann K.

Attach Hum Dev. 2018 Mar 29:1-8. doi: 10.1080/14616734.2018.1454054. [Epub ahead of print]

PMID:
29595079
6.

Similar survival of patients with multiple versus single primary melanomas based on Utah Surveillance, Epidemiology, and End Results data (1973-2011).

Grossman D, Farnham JM, Hyngstrom J, Klapperich ME, Secrest AM, Empey S, Bowen GM, Wada D, Andtbacka RHI, Grossmann K, Bowles TL, Cannon-Albright LA.

J Am Acad Dermatol. 2018 Aug;79(2):238-244. doi: 10.1016/j.jaad.2018.02.055. Epub 2018 Mar 1.

PMID:
29499295
7.

[Lübeck University Model for Physiotherapy].

Bretin A, Großmann K, Schulz A.

Gesundheitswesen. 2018 Feb 19. doi: 10.1055/s-0044-100040. [Epub ahead of print] German.

PMID:
29458224
8.

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.

Nebot N, Arkenau HT, Infante JR, Chandler JC, Weickhardt A, Lickliter JD, Sarantopoulos J, Gordon MS, Mak G, St-Pierre A, Tang L, Mookerjee B, Carson SW, Hayes S, Grossmann KF.

Br J Clin Pharmacol. 2018 Apr;84(4):764-775. doi: 10.1111/bcp.13488. Epub 2018 Jan 23.

9.

Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.

Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J, Robert C, Grossmann K, McDermott D, Walker D, Bhore R, Larkin J, Postow MA.

J Clin Oncol. 2017 Dec 1;35(34):3807-3814. doi: 10.1200/JCO.2017.73.2289. Epub 2017 Aug 25.

10.

Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.

Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL, Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D.

Melanoma Res. 2017 Oct;27(5):477-484. doi: 10.1097/CMR.0000000000000382.

11.

Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy.

Johnson MM, Leachman SA, Aspinwall LG, Cranmer LD, Curiel-Lewandrowski C, Sondak VK, Stemwedel CE, Swetter SM, Vetto J, Bowles T, Dellavalle RP, Geskin LJ, Grossman D, Grossmann KF, Hawkes JE, Jeter JM, Kim CC, Kirkwood JM, Mangold AR, Meyskens F, Ming ME, Nelson KC, Piepkorn M, Pollack BP, Robinson JK, Sober AJ, Trotter S, Venna SS, Agarwala S, Alani R, Averbook B, Bar A, Becevic M, Box N, E Carson W 3rd, Cassidy PB, Chen SC, Chu EY, Ellis DL, Ferris LK, Fisher DE, Kendra K, Lawson DH, Leming PD, Margolin KA, Markovic S, Martini MC, Miller D, Sahni D, Sharfman WH, Stein J, Stratigos AJ, Tarhini A, Taylor MH, Wisco OJ, Wong MK.

Melanoma Manag. 2017 Mar;4(1):13-37. doi: 10.2217/mmt-2016-0022. Epub 2017 Mar 1. Review.

12.

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, Gutzmer R, Linette G, Chmielowski B, Lao CD, Lorigan P, Grossmann K, Hassel JC, Sznol M, Daud A, Sosman J, Khushalani N, Schadendorf D, Hoeller C, Walker D, Kong G, Horak C, Weber J.

J Clin Oncol. 2018 Feb 1;36(4):383-390. doi: 10.1200/JCO.2016.71.8023. Epub 2017 Jul 3.

PMID:
28671856
13.

Treatment-related determinants of survival in early-stage (T1-2N0M0) oral cavity cancer: A population-based study.

Sowder JC, Cannon RB, Buchmann LO, Hunt JP, Hitchcock Y, Lloyd S, Grossmann KF, Monroe MM.

Head Neck. 2017 May;39(5):876-880. doi: 10.1002/hed.24679. Epub 2017 Feb 25.

PMID:
28236368
14.

Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis.

Sowa M, Trezzi B, Hiemann R, Schierack P, Grossmann K, Scholz J, Somma V, Sinico RA, Roggenbuck D, Radice A.

Medicine (Baltimore). 2016 Nov;95(44):e5225.

15.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

16.

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.

Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor DR, Salama AK, Taylor MH, Ott PA, Horak C, Gagnier P, Jiang J, Wolchok JD, Postow MA.

Lancet Oncol. 2016 Nov;17(11):1558-1568. doi: 10.1016/S1470-2045(16)30366-7. Epub 2016 Sep 9.

17.

Selectivity Enhancement by Using Double-Layer MOX-Based Gas Sensors Prepared by Flame Spray Pyrolysis (FSP).

Rebholz J, Grossmann K, Pham D, Pokhrel S, Mädler L, Weimar U, Barsan N.

Sensors (Basel). 2016 Sep 6;16(9). pii: E1437. doi: 10.3390/s16091437.

18.

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma.

Ray A, Williams MA, Meek SM, Bowen RC, Grossmann KF, Andtbacka RH, Bowles TL, Hyngstrom JR, Leachman SA, Grossman D, Bowen GM, Holmen SL, VanBrocklin MW, Suneja G, Khong HT.

Oncotarget. 2016 Sep 27;7(39):64390-64399. doi: 10.18632/oncotarget.10453.

19.

Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2.

Stenehjem DD, Toole M, Merriman J, Parikh K, Daignault S, Scarlett S, Esper P, Skinner K, Udager A, Tantravahi SK, Gill D, Straubhar AM, Agarwal AM, Grossmann KF, Samlowski WE, Redman B, Agarwal N, Alva A.

Cancer Immunol Immunother. 2016 Aug;65(8):941-9. doi: 10.1007/s00262-016-1854-1. Epub 2016 Jun 8.

PMID:
27277816
20.

Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG).

Anker CJ, Grossmann KF, Atkins MB, Suneja G, Tarhini AA, Kirkwood JM.

Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):632-46. doi: 10.1016/j.ijrobp.2016.01.038. Review. Erratum in: Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):486.

21.

Adjuvant treatment for patients with surgically resected advanced-stage melanoma.

Grossmann KF.

Clin Adv Hematol Oncol. 2015 Oct;13(10):633-5. Review. No abstract available.

PMID:
27058564
22.

Simultaneous detection of celiac disease-specific IgA antibodies and total IgA.

Grossmann K, Röber N, Hiemann R, Rödiger S, Schierack P, Reinhold D, Laass MW, Conrad K, Roggenbuck D.

Auto Immun Highlights. 2016 Dec;7(1):2. doi: 10.1007/s13317-016-0073-2. Epub 2016 Jan 30.

23.

Detection of Exosomal miRNAs in the Plasma of Melanoma Patients.

Pfeffer SR, Grossmann KF, Cassidy PB, Yang CH, Fan M, Kopelovich L, Leachman SA, Pfeffer LM.

J Clin Med. 2015 Dec 17;4(12):2012-27. doi: 10.3390/jcm4121957.

24.

Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications.

Grossmann KF, Margolin K.

Ther Adv Med Oncol. 2015 May;7(3):181-91. doi: 10.1177/1758834015572284. Review.

25.

Correction: A genetically defined asymmetry underlies the inhibitory control of flexor-extensor locomotor movements.

Britz O, Zhang J, Grossmann KS, Dyck J, Kim JC, Dymecki S, Gosgnach S, Goulding M.

Elife. 2015 Nov 25;4:e13038. doi: 10.7554/eLife.13038. No abstract available.

26.

A genetically defined asymmetry underlies the inhibitory control of flexor-extensor locomotor movements.

Britz O, Zhang J, Grossmann KS, Dyck J, Kim JC, Dymecki S, Gosgnach S, Goulding M.

Elife. 2015 Oct 14;4. doi: 10.7554/eLife.04718. Erratum in: Elife. 2015;4:e13038.

27.

A miniaturized blotting system for simultaneous detection of different autoantibodies.

Canzler U, Bartsch H, Großmann K, Lehmann W, Conrad K, Kurien BT, Dorri Y, Scofield RH, Bachmann MP.

Methods Mol Biol. 2015;1312:165-73. doi: 10.1007/978-1-4939-2694-7_20.

PMID:
26044001
28.

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD.

N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.

29.

Second generation analysis of antinuclear antibody (ANA) by combination of screening and confirmatory testing.

Scholz J, Grossmann K, Knütter I, Hiemann R, Sowa M, Röber N, Rödiger S, Schierack P, Reinhold D, Bogdanos DP, Meroni PL, Radice A, Conrad K, Roggenbuck D.

Clin Chem Lab Med. 2015 Nov;53(12):1991-2002. doi: 10.1515/cclm-2015-0083.

30.

Correction: Simultaneous Automated Screening and Confirmatory Testing for Vasculitis-Specific ANCA.

Sowa M, Grossmann K, Knütter I, Hiemann R, Röber N, Anderer U, Csernok E, Bogdanos DP, Borghi MO, Meroni PL, Schierack P, Reinhold D, Conrad K, Roggenbuck D.

PLoS One. 2015 May 13;10(5):e0127933. doi: 10.1371/journal.pone.0127933. eCollection 2015. No abstract available.

31.

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS.

N Engl J Med. 2015 May 21;372(21):2006-17. doi: 10.1056/NEJMoa1414428. Epub 2015 Apr 20.

32.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, Larkin J.

Lancet Oncol. 2015 Apr;16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. Epub 2015 Mar 18.

PMID:
25795410
33.

Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment.

Ly D, Bagshaw HP, Anker CJ, Tward JD, Grossmann KF, Jensen RL, Shrieve DC.

J Neurosurg. 2015 Aug;123(2):395-401. doi: 10.3171/2014.9.JNS141425. Epub 2015 Mar 13.

PMID:
25768829
34.

Identification of a spinal circuit for light touch and fine motor control.

Bourane S, Grossmann KS, Britz O, Dalet A, Del Barrio MG, Stam FJ, Garcia-Campmany L, Koch S, Goulding M.

Cell. 2015 Jan 29;160(3):503-15. doi: 10.1016/j.cell.2015.01.011.

35.

Clinical outcomes associated with evolving treatment modalities and radiation techniques for base-of-tongue carcinoma: thirty years of institutional experience.

Chen LA, Anker CJ, Hunt JP, Buchmann LO, Grossmann KF, Boucher K, Fang LM, Shrieve DC, Hitchcock YJ.

Cancer Med. 2015 May;4(5):651-60. doi: 10.1002/cam4.364. Epub 2015 Jan 26.

36.

Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.

Suttle AB, Grossmann KF, Ouellet D, Richards-Peterson LE, Aktan G, Gordon MS, LoRusso PM, Infante JR, Sharma S, Kendra K, Patel M, Pant S, Arkenau HT, Middleton MR, Blackman SC, Botbyl J, Carson SW.

J Clin Pharmacol. 2015 Apr;55(4):392-400. doi: 10.1002/jcph.437. Epub 2014 Dec 30.

PMID:
25449654
37.

Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.

Sowa M, Grossmann K, Knütter I, Hiemann R, Röber N, Anderer U, Csernok E, Bogdanos DP, Borghi MO, Meroni PL, Schierack P, Reinhold D, Conrad K, Roggenbuck D.

PLoS One. 2014 Sep 16;9(9):e107743. doi: 10.1371/journal.pone.0107743. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0120626. PLoS One. 2015;10(5):e0127933.

38.

Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ.

Duffy KL, Truong A, Bowen GM, Andtbacka RH, Hyngstrom J, Bowles T, Grossmann K, Khong H, Hyde M, Florell SR, Bowen AR, Wada D, Grossman D.

J Am Acad Dermatol. 2014 Oct;71(4):835-8. doi: 10.1016/j.jaad.2014.06.044. No abstract available.

39.

An Outbreak of Porcine Reproductive and Respiratory Syndrome Virus in Switzerland Following Import of Boar Semen.

Nathues C, Perler L, Bruhn S, Suter D, Eichhorn L, Hofmann M, Nathues H, Baechlein C, Ritzmann M, Palzer A, Grossmann K, Schüpbach-Regula G, Thür B.

Transbound Emerg Dis. 2016 Apr;63(2):e251-61. doi: 10.1111/tbed.12262. Epub 2014 Sep 11.

PMID:
25209832
40.

Sustained remission of Parkinson disease associated melanoma with immunotherapy.

Shprecher DR, Grossmann KF, Tward JD.

Parkinsonism Relat Disord. 2014 Sep;20(9):1027-9. doi: 10.1016/j.parkreldis.2014.05.017. Epub 2014 Jun 13. No abstract available.

PMID:
24997547
41.

Shp2/MAPK signaling controls goblet/paneth cell fate decisions in the intestine.

Heuberger J, Kosel F, Qi J, Grossmann KS, Rajewsky K, Birchmeier W.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3472-7. doi: 10.1073/pnas.1309342111. Epub 2014 Feb 18.

42.

Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp.

Terakedis BE, Anker CJ, Leachman SA, Andtbacka RH, Bowen GM, Sause WT, Grossmann KF, Bowles TL, Noyes RD, Hitchcock YJ, Boucher KM, Shrieve DC.

J Am Acad Dermatol. 2014 Mar;70(3):435-42. doi: 10.1016/j.jaad.2013.10.028. Epub 2013 Dec 24.

PMID:
24373782
43.

Maternal sensitivity: observational studies honoring Mary Ainsworth's 100(th) year.

Grossmann KE, Bretherton I, Waters E, Grossmann K.

Attach Hum Dev. 2013;15(5-6):443-7. doi: 10.1080/14616734.2013.841058. No abstract available.

PMID:
24299128
44.

A transcription factor code defines nine sensory interneuron subtypes in the mechanosensory area of the spinal cord.

Del Barrio MG, Bourane S, Grossmann K, Schüle R, Britsch S, O'Leary DD, Goulding M.

PLoS One. 2013 Nov 4;8(11):e77928. doi: 10.1371/journal.pone.0077928. eCollection 2013.

45.

Impact of Pt additives on the surface reactions between SnO2, water vapour, CO and H2; an operando investigation.

Großmann K, Wicker S, Weimar U, Barsan N.

Phys Chem Chem Phys. 2013 Nov 28;15(44):19151-8. doi: 10.1039/c3cp52782d.

PMID:
24105035
46.

Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.

Anker CJ, Ribas A, Grossmann AH, Chen X, Narra KK, Akerley W, Andtbacka RH, Noyes RD, Shrieve DC, Grossmann KF.

J Clin Oncol. 2013 Jun 10;31(17):e283-7. doi: 10.1200/JCO.2012.44.7755. Epub 2013 May 6. No abstract available.

PMID:
23650406
47.

Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma.

Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N, Gilreath JA.

Target Oncol. 2014 Mar;9(1):63-71. doi: 10.1007/s11523-013-0276-7. Epub 2013 Apr 23.

PMID:
23609056
48.

Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.

Ouellet D, Grossmann KF, Limentani G, Nebot N, Lan K, Knowles L, Gordon MS, Sharma S, Infante JR, Lorusso PM, Pande G, Krachey EC, Blackman SC, Carson SW.

J Pharm Sci. 2013 Sep;102(9):3100-9. doi: 10.1002/jps.23519. Epub 2013 Apr 22.

PMID:
23608920
49.

The small GTPase ARF6 stimulates β-catenin transcriptional activity during WNT5A-mediated melanoma invasion and metastasis.

Grossmann AH, Yoo JH, Clancy J, Sorensen LK, Sedgwick A, Tong Z, Ostanin K, Rogers A, Grossmann KF, Tripp SR, Thomas KR, D'Souza-Schorey C, Odelberg SJ, Li DY.

Sci Signal. 2013 Mar 5;6(265):ra14. doi: 10.1126/scisignal.2003398.

50.

Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis.

Knütter I, Hiemann R, Brumma T, Büttner T, Großmann K, Cusini M, Pregnolato F, Borghi MO, Anderer U, Conrad K, Reinhold D, Roggenbuck D, Csernok E.

Arthritis Res Ther. 2012 Dec 14;14(6):R271. doi: 10.1186/ar4119.

Supplemental Content

Loading ...
Support Center